Watch VBIO. Know when insiders buy.
One email the day a filing lands. Free.
VBIO
Valion Bio, Inc.
1.12
−0.07 −5.88%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $24.9MP/E —DIV YIELD —FCF YIELD -28.32%REV TTM —NET INCOME −$8.9MNET CASH —52W 1.12 – 73.75SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$6.4M | −$7.1M | — | -2.17 | −$5.3M | $57K | −$5.3M | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$5.6M | −$6.2M | — | -2.23 | −$5M | $7K | −$5M | Aug 14 |
| Q1 2026 · Mar 30 | — | — | — | — | — | — | — | — | — | — | May 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$2M | −$2.8M | — | -1.35 | −$2.3M | $25K | −$2.3M | Mar 30 |
| Q3 2025 · Sep 30 | $146K | +15.9% | -99.3% | −$2.5M | −$2.6M | — | -1.97 | −$2M | $10K | −$2M | Nov 14 |
| Q2 2025 · Jun 30 | $86K | −38.6% | 62.8% | −$1.7M | −$1.9M | — | -2.19 | −$1.8M | $3K | −$1.8M | Aug 14 |
| Q1 2025 · Mar 31 | $70K | −79.0% | 71.4% | −$1.4M | −$1.5M | — | -2.52 | −$889K | $0 | −$889K | Aug 14 |
| Q4 2024 · Dec 31derived | $180K | −49.6% | -132.8% | −$298K | −$1.5M | — | -18.61 | −$1.4M | $0 | −$1.4M | Mar 30 |
| Q3 2024 · Sep 30 | $126K | — | 34.9% | −$1.4M | −$1.4M | — | -0.23 | −$1.4M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | $140K | — | 21.4% | −$1.3M | −$1.3M | — | -5.37 | −$1.3M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | $334K | — | 50.0% | −$1.5M | −$1.5M | — | -17.15 | −$1.7M | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | $357K | — | 1.4% | −$2.2M | −$2.2M | — | -166.20 | −$1.8M | $0 | −$1.8M | Mar 21 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$7.9M | −$8.9M | — | -7.84 | −$7M | $38K | −$7M | — | — |
| FY2024 · to Dec 31 | $780K | 0.3% | −$4.5M | −$5.7M | -725.0% | -19.68 | −$5.7M | $0 | −$5.7M | — | — |
| FY2023 · to Dec 31 | $1.2M | 24.4% | −$8.2M | −$8.2M | -701.0% | -176.80 | −$8.5M | $118K | −$8.6M | — | — |
| FY2022 · to Dec 31 | $1.8M | 16.3% | −$10.1M | −$10.1M | -548.7% | -104.32 | −$8.9M | $11K | −$8.9M | — | — |
| FY2021 · to Dec 31 | $1.3M | -3.0% | −$5.6M | −$8.5M | -675.7% | -2.43 | −$5.6M | — | — | — | — |
Every number comes from Valion Bio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.